{"title":"Xenon和Genentech合作开发疼痛治疗和伴随诊断","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1678","DOIUrl":null,"url":null,"abstract":"Canadian Xenon Pharmaceuticals has formed its sixth major partnership by agreeing to collaborate with Roche’s Genentech on the discovery and development of novel compounds and companion diagnostics for the potential treatment of pain. The agreement is interesting in that Genentech will gain an exclusive licence to compounds and a non-exclusive licence to diagnostics for future development and commercialisation. The deal is potentially worth up to US$646 M to Xenon in research, development and commercialisation milestones for multiple products and indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"38 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I2.1678\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Canadian Xenon Pharmaceuticals has formed its sixth major partnership by agreeing to collaborate with Roche’s Genentech on the discovery and development of novel compounds and companion diagnostics for the potential treatment of pain. The agreement is interesting in that Genentech will gain an exclusive licence to compounds and a non-exclusive licence to diagnostics for future development and commercialisation. The deal is potentially worth up to US$646 M to Xenon in research, development and commercialisation milestones for multiple products and indications.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I2.1678\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I2.1678","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics
Canadian Xenon Pharmaceuticals has formed its sixth major partnership by agreeing to collaborate with Roche’s Genentech on the discovery and development of novel compounds and companion diagnostics for the potential treatment of pain. The agreement is interesting in that Genentech will gain an exclusive licence to compounds and a non-exclusive licence to diagnostics for future development and commercialisation. The deal is potentially worth up to US$646 M to Xenon in research, development and commercialisation milestones for multiple products and indications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
